Core G ? Proteomics and Systems Biology The Proteomics and Systems Biology Core G was created in 2010 in collaboration with the Case Center for Proteomics and Bioinformatics (CPB). The development of the Core was a direct response to increasing CFAR membership demand for proteomic services. The Core provides state-of-the-art proteomic instrumentation; computational resources and software for systems biology; proteomic methods development; consultation and training. Core G includes dedicated staff who are highly experienced in both structural and quantitative proteomics. Core G staff and CFAR faculty actively collaborate in grant proposals and development of novel technologies to advance CFAR members HIV related research. Over the past 5 years the faculty and staff from Core G have successfully partnered with CFAR scientists obtain $6.5 million in awards for HIV research where proteomics was an essential element. The project include the development novel assays, identification of biomarkers for HIV-induced chronic inflammation, and identification of targets for HIV infection and treatment. All these development projects are well aligned with the strategic foci of the CFAR working groups: Immunopathogenesis, Virology & Cure and Co-morbidities and Co-infections. With the recent recruitment of Dr. Rafick Skaly, who will become co-Director, the Core will be be able to dramatically expand the systems biology and bioinformatics tools available to HIV researchers. Dr. Mark Chance, Director, will continue to oversee the proteomics research. The Core plans to merge the sets of prioritary systems biology tools already available at CWRU with additional tools brought by Dr. Skaly and his team. In addition there will be investment in the development of new software to address challenging problems in analysis of ?omic scale data sets. Finally, Core G will work closely with the Virology, Next Generation Sequencing and Imaging Core, now co-Directed by Dr. Mark Cameron to analyze and compare large transcriptomic and proteomic data sets. The extensive data sets used to by Drs. Sekaly and Cameron to identify immune subset signatures and immune correlates of protection /pathogenesis panels will provide an invaluable resource for the CFAR's extensive programs on T-cell activation.
Our specific aims are: ? To provide advanced proteomic technologies to solve unmet needs in HIV research. ? To develop and apply systems biology tools to solve unmet challenges in analysis of `-omic' data. ? To provide consultation and training. In summary, the primary goal of Core G is to make advanced proteomic instrumentation and systems biology tools available to CFAR members for use in HIV research projects. The Core's skilled and highly approachable support staff assist investigators at every stage from experimental design to data analysis. Although Core G will continue to provide a drop-off service for routine analyses, its true strength lies in the active collaborations with CFAR investigators that have resulted in novel assays, identification of new biomarkers, and identified novel targets for combating HIV infection.

Public Health Relevance

Core G ? Proteomics and Systems Biology The HIV/AIDS pandemic is the single largest threat to global public health. This core provides advanced instruments and tools to help HIV researchers with experimental design and data analysis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036219-24
Application #
9468327
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
24
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Tomas, Myreen E; Mana, Thriveen S C; Wilson, Brigid M et al. (2018) Tapering Courses of Oral Vancomycin Induce Persistent Disruption of the Microbiota That Provide Colonization Resistance to Clostridium difficile and Vancomycin-Resistant Enterococci in Mice. Antimicrob Agents Chemother 62:
Yanik, Elizabeth L; Hernández-Ramírez, Raúl U; Qin, Li et al. (2018) Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. J Acquir Immune Defic Syndr 78:499-504
Sahmoudi, Karima; Abbassi, Hassan; Bouklata, Nada et al. (2018) Immune activation and regulatory T cells in Mycobacterium tuberculosis infected lymph nodes. BMC Immunol 19:33
Webel, Allison R; Moore, Shirley M; Longenecker, Chris T et al. (2018) Randomized Controlled Trial of the SystemCHANGE Intervention on Behaviors Related to Cardiovascular Risk in HIV+ Adults. J Acquir Immune Defic Syndr 78:23-33
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Eckard, Allison Ross; O'Riordan, Mary Ann; Rosebush, Julia C et al. (2018) Vitamin D supplementation decreases immune activation and exhaustion in HIV-1-infected youth. Antivir Ther 23:315-324
Webel, Allison R; Perazzo, Joseph; Longenecker, Christopher T et al. (2018) The Influence of Exercise on Cardiovascular Health in Sedentary Adults With Human Immunodeficiency Virus. J Cardiovasc Nurs 33:239-247
Yan, Junpeng; Shun, Ming-Chieh; Hao, Caili et al. (2018) HIV-1 Vpr Reprograms CLR4DCAF1 E3 Ubiquitin Ligase to Antagonize Exonuclease 1-Mediated Restriction of HIV-1 Infection. MBio 9:
Silver, Nicholas; Paynter, Mary; McAllister, Georgina et al. (2018) Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay. AIDS Res Ther 15:18
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150

Showing the most recent 10 out of 539 publications